Global Chemotherapy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019


◆タイトル:Global Chemotherapy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About CINV
CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.

The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.

Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.

Technavio’s analysts forecast the global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.

Technavio’s report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas

[Key vendors]
• GlaxoSmithKline
• Helsinn
• Heron Therapeutics
• Merck & Co
• Tesaro

[Other prominent vendors]
• Acacia Pharma
• Aphios
• Barr Laboratories
• Baxter Healthcare
• Eisai
• Especificos Stendhal
• F.Hoffmann La Roche
• Mundipharma
• Mylan Pharmaceuticals
• OPKO Health
• Orchid Healthcare
• Otsuka Pharmaceutical
• ProStrakan
• Sandoz (Novartis)
• Solvay Pharmaceuticals
• Specialised Therapeutics Australia
• Sun Pharma
• Taiho Pharmaceutical
• Teva Pharmaceuticals

[Market driver]
• Increase in incidence and prevalence of cancer
• For a full, detailed list, view our report

[Market challenge]
• Complex physiology of CINV
• For a full, detailed list, view our report

[Market trend]
• Increased use of combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?


PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Introduction

PART 05: Product profiles

PART 06: Disease Overview
Understanding the disease
Types of CINV
Risk factors
Economic burden

PART 07: Regulatory guidelines on CINV

PART 08: Pipeline analysis

PART 09: Market landscape
Market overview
Market size and forecast
CINV Drugs Market in US
Five forces analysis

PART 10: Market segmentation by ROA
Transdermal patch

PART 11: Market segmentation by onset of disease in CINV
Acute CINV
Delayed CINV
Anticipatory CINV
Breakthrough CINV

PART 12: Market segmentation by pharmacological class of drugs
5-HT3 Receptor Antagonists
NK-1 Receptor Antagonists
Dopamine Receptor Antagonists

PART 13: Market segmentation by type of therapy
Combination therapy

PART 14: Geographical segmentation

PART 15: Market drivers

PART 16: Impact of drivers

PART 17: Market challenges

PART 18: Impact of drivers and challenges

PART 19: Market trends

PART 20: Vendor landscape
Competitive Scenario
Market Share Analysis 2014
Other prominent vendors

PART 21: Key vendor analysis
Merck & Co. Inc.

PART 22: Appendix
List of abbreviation

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Types of CINV
Exhibit 03: Causes of emesis
Exhibit 04: Chemotherapeutic agents related emetic risk
Exhibit 05: Management of CINV
Exhibit 06: Summary of regulatory guidelines by ASCO, ESMO, MASCC, and NCCN for CINV treatment
Exhibit 07: Global CINV drugs market: Pipeline portfolio
Exhibit 08: Global CINV drugs market 2014-2019 ($ millions)
Exhibit 09: CINV drugs market in US 2014-2019 ($ millions)
Exhibit 10: Five forces analysis
Exhibit 11: Segmentation of global CINV drugs market by ROA
Exhibit 12: Global CINV drugs market segment by onset of disease
Exhibit 13: Global CINV drugs market segment by pharmacological class of drugs
Exhibit 14: Global CINV drugs market segment by type of therapy
Exhibit 15: Segmentation of Global CINV Drugs Market by Geography 2014
Exhibit 16: Drivers of global CINV drugs market
Exhibit 17: Impact of drivers
Exhibit 18: Challenges of global CINV drugs market
Exhibit 19: Impact of drivers and challenges
Exhibit 20: YoY growth and revenue of Emend 2011-2014 ($ millions)
Exhibit 21: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 22: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 24: Helsinn: products
Exhibit 25: Helsinn: Key pipeline products
Exhibit 26: Helsinn: Geographical presence
Exhibit 27: Heron: Product Pipeline
Exhibit 28: Merck & Co. Inc.: Business segmentation by revenue 2013
Exhibit 29: Merck & Co. Inc.: Business segmentation by revenue 2012 and 2013 (US$ billions)
Exhibit 30: Merck & Co. Inc.: Sales by geography 2013
Exhibit 31: Tesaro : Product segmentation
Exhibit 32: Tesaro : Geographical presence


GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck & Co, Tesaro, Acacia Pharma, Aphios, Barr Laboratories, Baxter Healthcare, Eisai, Especificos Stendhal, F.Hoffmann La Roche, Mundipharma, Mylan Pharmaceuticals, OPKO Health, Orchid Healthcare, Otsuka Pharmaceutical, ProStrakan, Sandoz (Novartis), Solvay Pharmaceuticals, Specialised Therapeutics Australia, Sun Pharma, Taiho Pharmaceutical, Teva Pharmaceuticals





★調査レポート[CINV(化学療法による悪心・嘔吐)治療薬の世界市場2015-2019] (Global Chemotherapy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019 / IRTNTR6836)販売に関する免責事項
[CINV(化学療法による悪心・嘔吐)治療薬の世界市場2015-2019] (Global Chemotherapy Induced Nausea and Vomitting (CINV) Drugs Market 2015-2019 / IRTNTR6836)についてEメールでお問い合わせ